Wall Street analyst estimates for GT Biopharma, Inc. (GTBP): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
GT Biopharma, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and bringing to market novel immuno-oncology treatments. Their innovative approach centers on a proprietary technology platform called Tri-specific Killer Engager (TriKE) fusion proteins, which are designed to harness the body's immune cells.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 4 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 5 |
| Avg rating (1-5) | 0.80 |
Valuation Ratios
| Price / Book | 3.40 |
| EV / EBITDA | -0.48 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | $1000 | $2000 | $7000 | $4000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -$1000 | -$2000 | -$7000 | -$4000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Research & Development | $975000 | $1.1M | $9.1M | $1.7M | $485000 | $9.6M | $8.8M | $6.5M | $5.8M | $3.5M |
| Selling, General & Admin | $8.4M | $134.5M | $12.5M | $9.8M | $6.3M | $47.9M | $12.4M | $7.1M | $8.6M | $8.9M |
| Operating Expenses | $9.4M | $135.6M | $21.6M | $11.5M | $6.8M | $57.5M | $21.3M | $13.6M | $14.4M | $12.4M |
| Operating Income | -$9.4M | -$135.6M | -$250.1M | -$11.5M | -$6.8M | -$57.5M | -$21.3M | -$13.6M | -$14.4M | -$12.4M |
| EBITDA | -$9.4M | -$135.6M | -$250.1M | -$36.5M | -$25.0M | -$57.5M | -$21.0M | $6.0M | -$13.2M | -$28.2M |
| Interest Expense | $6.6M | $8.6M | $9.1M | $2.1M | $3.3M | $718000 | $8000 | $213000 | 0 | $127000 |
| Pre-tax Income | $9.8M | -$144.2M | -$259.2M | -$38.6M | -$28.3M | -$58.0M | -$20.9M | -$7.6M | -$13.2M | -$28.4M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | $9.8M | -$144.2M | -$259.2M | -$38.6M | -$28.3M | -$58.0M | -$20.9M | -$7.6M | -$13.2M | -$28.4M |
| EPS | $1530000.00 | $-3630.50 | $-2192.50 | $-285.50 | $-161.25 | $-51.50 | $-16.50 | $-141.00 | $-173.50 | $-156.25 |
| EPS (Diluted) | $1530000.00 | $-3630.50 | $-2192.50 | $-285.50 | $-161.25 | $-51.50 | $-16.50 | $-141.00 | $-173.50 | $-156.25 |
| Shares Outstanding (Diluted) | $6 | $39457 | $118200 | $135400 | $175400 | $1.1M | $1.3M | $53920 | $75880 | $220530 |
Price
| Price | $7.81 |
| Market Cap | $10M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ARTL · CARM · DRMA · LIPO · PBM · PTIX · REVB
Explore sector: Healthcare · Biotechnology
More sections of GTBP: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks